MDL No. 2100 -- IN RE: Yasmin and Yaz (Drospirenone) Marketing and Sales Practices and Products Liability Litigation -- Assigned To Southern District of Illinois
(Posted by Tom Lamb at DrugInjuryWatch.com)
UPDATE: Our Focus Page on YAZ / Yasmin / Ocella has a complete collection of our articles about these birth control pills as well as selected news reports about YAZ, Yasmin, and Ocella.
UPDATE: Visit the YAZ, Yasmin, and Ocella Information page at our Drug Injury Law web site for more recent developments regarding personal injury and wrongful death lawsuits that involve YAZ, Yasmin, and Ocella.
On October 1, 2009 the United States Judicial Panel on Multidistrict Litigation (JPML) filed its Transfer Order which serves to consolidate all Yaz and Yasmin personal injury and wrongful death cases filed in federal court in a U.S. Code Section 1407 Multidistrict Litigation, or MDL.
MDL No. 2100 was assigned to the Southern District of Illinois according to this October 1 Transfer Order, with U.S. District Court Judge David R. Herndon presiding over these Yaz and Yasmin cases for "coordinated or consolidated pretrial proceedings".
In relevant part, from the JPML Yasmin and Yaz Transfer Order for MDL No. 2100:
On the basis of the papers filed and hearing session held, we find that these 32 actions involve common questions of fact, and that centralization under Section 1407 in the Southern District of Illinois will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. All actions share factual questions relating to at least one of the drospirenone-containing oral contraceptives Yaz and Yasmin, which are manufactured by Bayer. Plaintiffs in the products liability actions challenge the safety of those oral contraceptives and bring claims for personal injuries or wrongful death stemming from use of the drugs....
Yaz and Yasmin, as well as the generic Ocella, have been associated with various serious side effects, including deep vein thrombosis (DVT), pulmonary embolism (PE), and ischemic stroke (CVA).
The official name given to MDL No. 2100 is IN RE: Yasmin and Yaz (Drospirenone) Marketing and Sales Practices and Products Liability Litigation.
DrugInjuryLaw.com: Legal Information And News About Prescription Drug Side Effects